Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Lymphoma, Extranodal NK-T-Cell × selinexor × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 2 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma 1 Leukemia, Myelomonocytic, Chronic 1 Extensive Stage Lung Small Cell Cancer 1 Carcinoma, Pancreatic Ductal 1 Carcinoma 1

Interventions

pegaspargase 2 sugemalimab 1 selinexor 1 Thiotepa 1 Oxaliplatin 1 Immune Checkpoint Inhibitors 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06573138 2024-08-27

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Ruijin Hospital

Phase 2 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡